Combining genetic insights, biomarker assessment, and provider guidance creates a comprehensive picture for personalized supplementation decisions
Venter C, Meyer RW, Nwaru BI, Roduit C, Untersmayr E, Adel-Patient K, Agache I, Agostoni C, Akdis CA, Bischoff SC, du Toit G, Feeney M, Frei R, Garn H, Greenhawt M, Hoffmann-Sommergruber K, Lunjani N, Maslin K, Mills C, Muraro A, Pali-Schll I, Poulson LK, Reese I, Renz H, Roberts GC, Smith P, Smolinska S, Sokolowska M, Stanton C, Vlieg-Boerstra B, OMahony L
Oleanolic acid-derived bardoxolone methyl, a dual activator of Nrf2 and inhibitor of the NF-B pathway, entered clinical trials for the treatment of diabetic nephropathy and chronic kidney disease (de Zeeuw et al
Curr Pharm Des 20(7):11211125 Seiwerth S, Rucman R, Turkovic B, Sever M, Klicek R, Radic B, et al (2018) BPC 157 and standard angiogenic growth factors